{"product_id":"tesamorelin-10mg","title":"Tesamorelin 10mg","description":"\u003cp\u003e\u003cstrong\u003eBuy high-purity tesamorelin (10mg) in Australia. Third-party lab tested at \u0026gt;99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch2\u003eAbout tesamorelin\u003c\/h2\u003e\n\u003cp\u003eTesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH 1–44), modified at the N-terminus with a trans-3-hexenoyl group that markedly increases its resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). The modification gives tesamorelin a substantially longer functional half-life than native GHRH while preserving its ability to bind and activate the GHRH receptor on pituitary somatotrophs.\u003c\/p\u003e\n\n\u003cp\u003eIn published research, tesamorelin is one of the most extensively characterised GHRH analogues, with study interest concentrated on the GH\/IGF-1 axis, visceral adipose tissue dynamics and metabolic markers in animal and human research populations.\u003c\/p\u003e\n\u003cp\u003eOptic Labs supplies tesamorelin as a lyophilised powder in 10mg research vials, third-party HPLC tested to \u0026gt;99% purity. The product is distributed Australian-domestic from Sydney, NSW, for in vitro and laboratory research applications. Tesamorelin is supplied strictly for laboratory research, development or analytical use and is not intended for human consumption.\u003c\/p\u003e\n\n\u003ch2\u003eProduct specifications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompound:\u003c\/strong\u003e Tesamorelin (trans-3-hexenoyl-GHRH 1–44)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCAS number:\u003c\/strong\u003e 218949-48-5\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular formula:\u003c\/strong\u003e C\u003csub\u003e221\u003c\/sub\u003eH\u003csub\u003e366\u003c\/sub\u003eN\u003csub\u003e72\u003c\/sub\u003eO\u003csub\u003e67\u003c\/sub\u003eS\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e ~5196 g\/mol\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSequence:\u003c\/strong\u003e trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH\u003csub\u003e2\u003c\/sub\u003e (44 amino acids)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% by HPLC\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAvailable size:\u003c\/strong\u003e 10mg vial\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e 2–8°C, protect from light. Reconstituted: 2–8°C, used within 30 days.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrigin:\u003c\/strong\u003e Manufactured to research-grade specifications, third-party HPLC verified\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShipping:\u003c\/strong\u003e Australia-wide domestic dispatch from Sydney, NSW\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eResearch background\u003c\/h2\u003e\n\u003cp\u003eTesamorelin was originally developed by Theratechnologies in the early 2000s as a stabilised analogue of human GHRH, with the trans-3-hexenoyl N-terminal modification specifically engineered to resist DPP-IV cleavage.\u003c\/p\u003e\n\n\u003cp\u003eThe compound has been extensively studied in published clinical and preclinical research, most notably in the context of HIV-associated visceral adipose tissue accumulation, where it became the first GHRH analogue to receive a regulatory indication in that population.\u003c\/p\u003e\n\n\u003cp\u003eIn Australian and broader research contexts, tesamorelin is examined as a research-use compound for studying GHRH-axis biology.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRH receptor pharmacology:\u003c\/strong\u003e in pituitary cell-culture studies, tesamorelin binds the GHRH receptor with affinity comparable to native GHRH 1–44 and stimulates pulsatile growth hormone release through the cAMP\/PKA pathway.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGH and IGF-1 axis research:\u003c\/strong\u003e in published research populations, tesamorelin administration has been associated with sustained increases in endogenous GH pulse amplitude and downstream IGF-1, without the supraphysiological GH exposures seen with exogenous recombinant GH.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eVisceral adipose tissue research:\u003c\/strong\u003e in published lipodystrophy studies, tesamorelin has been investigated for its effects on visceral adipose tissue volume measured by CT or MRI, with research interest in the lipolytic effects of restored physiological GH pulsatility.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMetabolic markers:\u003c\/strong\u003e research has examined effects on triglycerides, non-HDL cholesterol, adiponectin and hepatic fat fraction in study populations with metabolic dysregulation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHepatic steatosis models:\u003c\/strong\u003e in published research on non-alcoholic fatty liver disease (NAFLD) cohorts, tesamorelin has been studied for effects on liver fat content and markers of hepatic inflammation and fibrosis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCognitive and neurological research:\u003c\/strong\u003e exploratory research has examined tesamorelin in the context of GH-axis modulation and cognitive performance in older research populations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePharmacokinetic stability:\u003c\/strong\u003e the trans-3-hexenoyl modification gives tesamorelin a functional duration of action sufficient to support once-daily dosing protocols in published research, in contrast to the very short half-life of native GHRH.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a plain-language overview of peptides, see our \u003ca href=\"\/blogs\/news\/what-are-peptides-australia-explainer\"\u003ewhat are peptides explainer\u003c\/a\u003e. Researchers working with reconstitution should also reference our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003epeptide reconstitution guide\u003c\/a\u003e, and for laboratory injection protocols our \u003ca href=\"\/blogs\/news\/how-to-inject-peptides-subcutaneous-protocol\"\u003esubcutaneous injection protocol article\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eReconstitution and handling\u003c\/h2\u003e\n\u003cp\u003eTesamorelin is supplied as a lyophilised powder and must be reconstituted with bacteriostatic water before use in any laboratory protocol. A common laboratory approach for the 10mg vial is reconstitution in 2ml of \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e to yield a 5mg\/ml working stock, or in 1ml for a 10mg\/ml stock.\u003c\/p\u003e\n\n\u003cp\u003eThe bacteriostatic water should be drawn into a sterile syringe and injected slowly down the inside wall of the lyophilised vial, allowing the peptide cake to dissolve passively rather than through agitation. Tesamorelin is sensitive to heat and freeze-thaw cycling; reconstituted stocks should be aliquoted, refrigerated at 2–8°C and protected from light, with research stocks typically used within 30 days.\u003c\/p\u003e\n\n\u003cp\u003eFor dilution maths across alternative volumes, see our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003ereconstitution calculator guide\u003c\/a\u003e. For long-term storage protocols, see our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eCommonly stacked research peptides\u003c\/h2\u003e\n\u003cp\u003eIn published research and laboratory protocols, tesamorelin is often examined alongside other GH-axis, metabolic and longevity research compounds:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/cjc-1295-no-dac-ipamorelin-10mg\"\u003eCJC-1295 + Ipamorelin\u003c\/a\u003e — GHRH\/GHRP combination commonly co-investigated with tesamorelin in research on the GH-axis and pulsatile GH release.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/aod-9604-5mg\"\u003eAOD-9604\u003c\/a\u003e — GH fragment studied alongside tesamorelin in adipose tissue and lipolysis research models.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/reta-10mg-15mg-20mg-30mg\"\u003eRetatrutide\u003c\/a\u003e — GLP-1\/GIP\/glucagon triple agonist examined in parallel with tesamorelin in metabolic and visceral adiposity research designs.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/mots-c-10mg-40mg\"\u003eMOTS-c\u003c\/a\u003e — mitochondrial-derived peptide investigated for metabolic and energy-balance effects alongside GH-axis research.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/nad-1000mg\"\u003eNAD+\u003c\/a\u003e — co-investigated in metabolic and longevity research alongside GH-axis modulation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor broader context on combined research designs, see our \u003ca href=\"\/blogs\/news\/peptide-research-stacks-australia-combinations\"\u003epeptide research stacks overview\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently asked questions\u003c\/h2\u003e\n\n\u003ch3\u003eIs tesamorelin legal in Australia?\u003c\/h3\u003e\n\u003cp\u003eTesamorelin is not currently registered with the Therapeutic Goods Administration (TGA) for any therapeutic indication in Australia. Optic Labs supplies tesamorelin strictly as a research chemical for in vitro and preclinical laboratory research — not for human consumption, clinical use or any therapeutic application. For a full overview of how the TGA treats research peptides in Australia, see our \u003ca href=\"\/blogs\/news\/are-peptides-legal-australia-tga-compliance-2025\"\u003epeptide legality and TGA compliance guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is tesamorelin?\u003c\/h3\u003e\n\u003cp\u003eTesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH 1–44), modified at the N-terminus with a trans-3-hexenoyl group that resists enzymatic degradation. In published research it stimulates pulsatile endogenous GH release through the GHRH receptor on pituitary somatotrophs. For a plain-language overview of peptides, see our \u003ca href=\"\/blogs\/news\/what-are-peptides-australia-explainer\"\u003ewhat are peptides explainer\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhat does tesamorelin do in published research?\u003c\/h3\u003e\n\u003cp\u003eIn published clinical and preclinical research, tesamorelin is studied for its effects on endogenous GH pulse amplitude, IGF-1 levels, visceral adipose tissue volume, hepatic fat fraction and a range of metabolic markers including triglycerides and adiponectin. These observations are research findings only and do not constitute therapeutic claims.\u003c\/p\u003e\n\n\u003ch3\u003eHow does tesamorelin compare with CJC-1295 in research?\u003c\/h3\u003e\n\u003cp\u003eBoth tesamorelin and CJC-1295 are GHRH analogues, but they differ in design.\u003c\/p\u003e\n\n\u003cp\u003eTesamorelin is the full GHRH 1–44 sequence with an N-terminal trans-3-hexenoyl modification for DPP-IV resistance and is supported by the largest published clinical research dataset of any GHRH analogue. \u003ca href=\"\/products\/cjc-1295-no-dac-ipamorelin-10mg\"\u003eCJC-1295 (no DAC)\u003c\/a\u003e is a shorter GHRH 1–29 analogue with several amino acid substitutions for stability, and is most often studied in combination with a ghrelin-receptor agonist such as ipamorelin.\u003c\/p\u003e\n\n\u003ch3\u003eHow is tesamorelin supplied?\u003c\/h3\u003e\n\u003cp\u003eOptic Labs supplies tesamorelin as a lyophilised powder in 10mg glass research vials. Each vial is sealed with a tamper-evident closure. Certificates of analysis showing HPLC purity testing are available on request.\u003c\/p\u003e\n\n\u003ch3\u003eHow much bacteriostatic water do I mix with a 10mg tesamorelin vial?\u003c\/h3\u003e\n\u003cp\u003eFor a 10mg vial, 2ml of \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e yields a 5mg\/ml working stock; 1ml yields a 10mg\/ml stock; 5ml yields a 2mg\/ml stock. Choose a volume based on the concentrations required by the research protocol. For a worked example with unit conversions, see our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003ereconstitution calculator guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eHow should reconstituted tesamorelin be stored?\u003c\/h3\u003e\n\u003cp\u003eReconstituted tesamorelin should be stored at 2–8°C, protected from light, and used within approximately 30 days. For longer-term storage, aliquoting and freezing at −20°C or below is preferred to limit freeze-thaw degradation. Full handling protocols are covered in our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage research guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhere does Optic Labs ship to?\u003c\/h3\u003e\n\u003cp\u003eOptic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.\u003c\/p\u003e\n\n\u003ch2\u003eLegal disclaimer\u003c\/h2\u003e\n\u003cp\u003eAll products on this site are supplied for \u003cstrong\u003elaboratory research, development or analytical use only\u003c\/strong\u003e. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the \u003cstrong\u003eTherapeutic Goods Administration (TGA)\u003c\/strong\u003e or the \u003cstrong\u003eAPVMA\u003c\/strong\u003e and are not intended to diagnose, treat, cure or prevent any disease.\u003c\/p\u003e\n\n\u003cp\u003eOptic Labs is not a \u003cstrong\u003ecompounding pharmacy\u003c\/strong\u003e or manufacturing facility as defined under the \u003cem\u003eTherapeutic Goods Act 1989\u003c\/em\u003e, and is not a registered provider of scheduled medicines or therapeutic goods.\u003c\/p\u003e","brand":"Optic Labs","offers":[{"title":"Default Title","offer_id":53360884089016,"sku":null,"price":142.99,"currency_code":"AUD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0952\/4196\/1656\/files\/tesa10.png?v=1776426119","url":"https:\/\/opticlabsau.com\/products\/tesamorelin-10mg","provider":"Optic Labs","version":"1.0","type":"link"}